COVID-19 Clinical Trials and Expanded Access

The aim of this study is to analyze the impact of video dance class and unsupervisedphysical activity on clinical-functional parameters, self-isolation and non-motorssymptoms in people with Parkinson's disease during the Covid-19 pandemic.

This is a pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BIDcompared to placebo to treat hospitalized patients with non-critical COVID-19.

We hypothesize that the intake of Omni-Biotic® 10 AAD can reduce intestinal inflammationand improves dysbiosis in Covid-19 disease. We further hypothesize that Omni-Biotic® 10AAD can reduce the duration of diarrhea, stool frequency, improve stool consistency,improve other gastrointestinal symptoms of Covid-19, reduce disease duration andseverity.The investigators aim to perform a randomized, double blind, placebo-controlled studyusing telemedicine in patients with Covid-19 disease.

Primary Objective:To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agentin patients with relapsed and refractory multiple myeloma (RRMM) and relapsed andrefractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose(RP2D)Secondary Objectives: - To characterize the safety profile of SAR442257 - To characterize the pharmacokinetics (PK) profile of SAR442257 - To assess preliminary evidence of antitumor activity

The VIGIL study was set up at the beginning of the pandemic, in the spring of 2020, at atime when diagnostic testing for SARS-CoV-2 had to be performed according to specificclinical criteria (even if no clinical picture suggestive of COVID had been clearlyidentified). The management of sick young children (with respiratory tract infection thatcould be attributed to COVID) by pediatricians (infectious diseases specialists,emergency physicians, general practitioners, and outpatients) was facilitated by analgorithm whose objective was to help define the indications for SARS-CoV-2 PCR andsubsequently for antigenic testing. The current technique of deep nasopharyngeal swabbing(for PCR or antigenic testing) is delicate and difficult in children, and is therefore aserious handicap for community-based screening, especially since infectious episodes arefrequent in children. Since then, nasal self-tests that can be easily used in childrenhave been commercialized and have facilitated screening.Because of the similarity between the clinical signs of respiratory tract infections inchildren, it is often impossible to distinguish between different viral respiratoryinfections and epidemics may overlap in time. However, the identification of the pathogenis the key to improve management of these infectious diseases. The VIGIL study istherefore continuing, still facilitated by the existence of an active pediatric networkexisting for 20 years. ACTIV AFPA and GPIP have created networks of hospital andambulatory pediatricians who actively participate in various observatorieshttps://www.jpeds.com/article/S0022-3476(17)31606-2/fulltext To date, these observatorieshave resulted in the publication of more than 80 articles in international journals(https://www.activ-france.com/fr/publications).

The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant fortreatment and to assess the potential in reducing mortality and morbidity rates inCOVID-19 patients. The study was approved by the ethical committee of the Egyptian Centerfor Research and Regenerative Medicine in 11-5-2020.

Background:COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract.Some people who get COVID-19 have only mild symptoms. But for others, infection leads topneumonia, respiratory failure, and, in some cases, death. Researchers want to learn moreabout any effects that may persist after people recover from COVID-19.Objective:To learn about any long-term medical problems that people who have recovered fromCOVID-19 might have, and whether they develop an immune response to SARS-CoV-2 thatprovides protection against reinfection.Eligibility:People age 18 and older who have recovered from documented COVID-19 or were in closecontact with someone who had COVID-19 but did not get the infectionDesign:Participants will be screened over 2 visits. During visit 1, they will answer questionsabout any symptoms they are having and will be tested for SARS-CoV-2 infection which willinvolve a nasal swab sample or other FDA approved test. If the test is negative, theywill proceed to the second visit, which will include:Physical examinationMedical historyMental health interview (which may be recorded if the participant agrees)Chest x-ray (for recovered COVID-19 participants only)Blood and urine testsPregnancy test (if needed)Lung function test (for recovered COVID-19 participants only)6-minute walk test (for recovered COVID-19 participants only)Questionnaires about their general and mental healthLeukapheresis to collect white blood cells (optional).Participants will be put into 1 of 2 groups: the COVID-19 group or the close contactgroup.Participants will have study visits every 6 months for 3 years. They will repeat some ofthe screening tests. Participants in the COVID-19 group may have visits more often ifthey develop symptoms that suggest re-infection with SARS-CoV-2.

This study aims to evaluate the impact of the COVID-19 pandemic and its measures onlifestyle in Dutch children between 4 - 18 years.

Antioxidants, and particularly polyphenols, have shown protection in respiratorypathologies, which is related to the decrease in the severity of the clinical picture andsuppression of inflammation. This suppression of inflammation may be related to theinhibition of NF-kB polyphenols, where its activation is related to the stimulation of150 stimuli including cytokines (IL-1β, IL-6, THF-α, GM-CSF, MCP-1), TLRs, among others.There may be other additional mechanisms that can help control virus-induced respiratorypathologies, among which are the regulation of reactive oxygen species (ROS) associatedwith tissue destruction caused by the virus and a selective antiviral action can bereported. direct.The standardized P2Et extract obtained from C. spinosa, by the Immunobiology Group of thePontificia Universidad Javeriana, is highly antioxidant, decreases lipid peroxidation andtissue damage and induces complete autophagy in stressed or tumor cells. The induction ofa full autophagic flow could inhibit the replication of beta-coronaviruses likeSARS-CoV-2. Furthermore, P2Et can decrease the factors involved in tissue damage byreducing IL-6 and decrease ILC2 cells of the lung in animals with lung metastases(unpublished data).These antecedents suggest that the supplementation of patients with COVID-19 with theextract P2Et, could improve their general condition and decrease the inflammatorymediators and the viral load.

In light of the rapidly emerging pandemic of SARS-CoV-2 infections, the global populationand health care systems are facing unprecedented challenges through the combination oftransmission and the potential for severe disease. Acute respiratory distress syndrome(ARDS) has been found with unusual clinical features dominated by substantial alveolarfluid load. It is unknown whether this is primarily caused by endothelial dysfunctionleading to capillary leakage or direct virus induced damage. This knowledge gap issignificant because the initial balance between fluid management and circulatory supportappear to be decisive. On progression of the disease, bacterial superinfectionfacilitated by inflammation and virus related damage, has been identified as the mainfactor for patient outcome, but the role of the host versus the environment microbiomeremains unclear.The overarching aim of the present research proposal is to improve therapeutic strategiesin critically ill patients with ARDS due to SARS-CoV-2 infection by advancing thepathophysiological understanding of this novel disease. This research thus focuses oninflammation, microcirculatory dysfunction and superinfection, aiming to elucidate riskfactors (RF) for the development of severe ARDS in SARS-CoV-2 infected patients andcontribute to the rationale for therapeutic strategies. The hypotheses are that (I) theprimary damage to the lung in SARS-CoV-2 ARDS is mediated through an exaggeratedpro-inflammatory response causing primary endothelial dysfunction, and subsequentlyacting two-fold on the degradation of the lung parenchyma - through the primary cytokineresponse, and through recruitment of the inflammatory-monocyte-lymphocyte-neutrophilaxis. The pronounced inflammation and primary damage to the lung disrupts the pulmonarymicrobiome, leading secondarily to pulmonary superinfections. (II) Pulmonary bacterialsuperinfections are a significant cause of morbidity and mortality in COVID-19 patients.Pathogen colonization main Risk Factor for lower respiratory tract infections. Toestablish colonization, pathogens have to interact with the local microbiota (a.k.a.microbiome) and certain microbiome profiles will be more resistant to pathogen invasion.Finally, (III) Handheld devices used in clinical routine are a potential reservoir andcarrier of both, SARS-CoV-2, as well as bacteria causing nosocomial pneumonia.